Blackstone’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRS
BCM
Blackstone's ACRS Position: Q2 2024 in Review
Blackstone sold out of Aclaris Therapeutics (ACRS) in Q2 2024, closing a stake of 13,033 shares — an estimated $16.2K sold.
Blackstone first reported a position in ACRS in Q4 2021 and held it in 10 quarters. The position peaked at $8.64M in Q3 2023. 98 funds tracked by Wall St. Rank hold ACRS as of Q2 2024.
- Blackstone reported no remaining Aclaris Therapeutics position as of Q2 2024 after selling out during the quarter.
- Blackstone sold 13,033 Aclaris Therapeutics shares in Q2 2024, an estimated $16.2K.
- Blackstone first reported a position in Aclaris Therapeutics in Q4 2021 and held it in 10 quarters.
- Blackstone's Aclaris Therapeutics position peaked at $8.64M in Q3 2023.
- 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2024.
Based on Blackstone's 13F filing for Q2 2024, filed 14 Aug 2024.